Aptose Biosciences Inc. (NASDAQ:APTO) Q1 2023 Earnings Conference Call May 8, 2023 5:00 PM ET

Company Participants

Susan Pietropaolo – Corporate Communications & Investor Relations

William G. Rice – Chairman, President and Chief Executive Officer

Rafael Bejar – Senior Vice President and Chief Medical Officer

Fletcher Payne – Senior Vice President and Chief Financial Officer

Conference Call Participants

Edward Tenthoff – Piper Sandler & Co.

Li Watsek – Cantor Fitzgerald

Joseph Pantginis – H.C. Wainwright

Operator

Good afternoon. My name is Antoine Alexander and I will be your conference operator today. I would like to welcome everyone to the Aptose Biosciences Reports Results for the First Quarter Ended March 31, 2023. At this time, all participants are in listen-only mode. After the speakers’ presentation, there will be a Q&A session. [Operator Instructions] Please be advised that today’s conference is being recorded.

I would now like to introduce Ms. Susan Pietropaolo. Please go ahead.

Susan Pietropaolo

Thank you, Antoine. Good afternoon and welcome to the Aptose Biosciences conference call to discuss financial and operational results for the first quarter ended March 31, 2023. Earlier today, Aptose issued a press release relating to these financial results. The news release as well as related SEC filings are accessible on Aptose’s website. Joining me on today’s call are Dr. William G. Rice, Chairman, President and CEO; Dr. Rafael Bejar, Senior Vice President and Chief Medical Officer; and Mr. Fletcher Payne, Senior Vice President and Chief Financial Officer.

Before we proceed, I would like to remind everyone that certain statements made during this call will include forward-looking statements within the meaning of U.S. and Canadian Securities Laws. Forward-looking statements reflect Aptose’s current expectations regarding future events. They are not guarantees of performance and it is possible that actual results and performance could differ materially from these stated expectations. They involve known and unknown risks, uncertainties and assumptions that may cause actual results, performance, and achievements to differ materially from those expressed. To learn more about these risks and uncertainties, please read the risk factors set forth in Aptose’s most recent annual report on Form 10-K and SEC and SEDAR filings.. All forward-looking statements made during this call speak only as of the date they’re made. Aptose undertakes no obligation to revise or update the statements to reflect events or circumstances after the date of this call, except as required by law.

I’ll now turn the call over to Dr. Rice, Chairman, President and CEO of Aptose Biosciences. Dr. Rice?